Cereno Scientific: Nomination committee appointed ahead of annual general meeting 2024
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the representatives of the nomination committee have been appointed ahead of the annual general meeting 2024. The nomination committee has been appointed in accordance with the principles for the nomination committee which were established by the annual general meeting on June 1, 2023.According to the principles for the nomination committee that were resolved at the annual general meeting on June 1, 2023, the nomination committee should